Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Assertio Therapeutics, Inc. reported financial results for the quarter ended March 31, 2019, and provided an update on its business performance and strategic initiatives.
TLC announced financial results for the first quarter ended March 31, 2019, and provided a business update.
Esperion provided bempedoic acid franchise development program updates and financial results for the first quarter ended March 31, 2019.
Epigenomics AG announced the financial results for the first quarter of the FY 2019.
Four biotech companies began trading on the Nasdaq this morning. Here’s a look at today’s launches and one rumored IPO.
Companies from across the globe provide updates to their pipelines and businesses, with news from BioNTech, Mologic, Akcea, RedHill, and more.
Under the terms of the deal, Pfizer will pay $340 million up front with another $470 million in payments contingent on milestones for the development and commercialization of TA-46 for the treatment of achondroplasia.
MorphoSys AG reports results for the first quarter of 2019.
Retrophin, Inc. reported its first quarter 2019 financial results and provided a corporate update.
Vericel Corporation reported financial results for the first quarter ended March 31, 2019, and recent business highlights.